Relmada Therapeutics, Inc. RLMD Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Relmada Therapeutics, Inc. (RLMD) reported cash provided by (used in) financing activity, including discontinued operation of $156.57M in Q1 2026.
- What is the long-term trend for Relmada Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Over 2 years (2021 to 2023), Relmada Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a -97.7% compound annual growth rate (CAGR), from $187.94M to -$98.46K.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.